BeiGene Switches To Combo Therapy Approach For Brukinsa

 
• By Dexter Jie Yan
  
BeiGene is ending Brukinsa's head-to-head clinical studies versus Imbruvica.
BeiGene ending Brukinsa's head-to-head studies versus Imbruvica • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia